BOLD Company Profile and Key Details
NASDAQ : BOLD
Boundless Bio
$1.49
-0.06-3.87%
At Close 4:00 PMPrice Chart
Stock Price Today
Boundless Bio, Inc. (BOLD) stock declined over -3.87%, trading at $1.49 on NASDAQ, down from the previous close of $1.55. The stock opened at $1.54, fluctuating between $1.49 and $1.56 in the recent session.
Stock Snapshot
1.55
Prev. Close
33.47M
Market Cap
1.49
Day Low
-0.6
P/E Ratio
-2.49
EPS (TTM)
N/A
Cash Flow per Share
1.54
Open
22.46M
Number of Shares
1.56
Day High
73.54%
Free Float in %
N/A
Book Value
157.85K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 15, 2026 | 1.56 | 1.56 | 1.49 | 1.49 | 157.85K |
| May 14, 2026 | 1.56 | 1.58 | 1.52 | 1.55 | 282.89K |
| May 13, 2026 | 1.52 | 1.58 | 1.49 | 1.54 | 118.66K |
| May 12, 2026 | 1.57 | 1.59 | 1.46 | 1.50 | 259.83K |
| May 11, 2026 | 1.41 | 1.58 | 1.40 | 1.55 | 332.13K |
| May 08, 2026 | 1.52 | 1.56 | 1.41 | 1.44 | 399.34K |
| May 07, 2026 | 1.59 | 1.65 | 1.51 | 1.53 | 115.95K |
| May 06, 2026 | 1.54 | 1.59 | 1.51 | 1.58 | 81.3K |
| May 05, 2026 | 1.59 | 1.59 | 1.53 | 1.57 | 86.66K |
| May 04, 2026 | 1.56 | 1.59 | 1.56 | 1.57 | 28.02K |
| Apr 30, 2026 | 1.47 | 1.48 | 1.43 | 1.46 | 73.69K |
| Apr 29, 2026 | 1.46 | 1.48 | 1.42 | 1.45 | 67.78K |
| Apr 28, 2026 | 1.49 | 1.50 | 1.43 | 1.44 | 142.26K |
| Apr 27, 2026 | 1.54 | 1.54 | 1.46 | 1.47 | 60.25K |
| Apr 23, 2026 | 1.56 | 1.56 | 1.48 | 1.52 | 95.68K |
| Apr 22, 2026 | 1.56 | 1.61 | 1.53 | 1.55 | 200.66K |
| Apr 21, 2026 | 1.60 | 1.61 | 1.56 | 1.58 | 73.44K |
| Apr 20, 2026 | 1.58 | 1.61 | 1.53 | 1.60 | 187.52K |
| Apr 17, 2026 | 1.64 | 1.65 | 1.57 | 1.58 | 302.42K |
| Apr 16, 2026 | 1.64 | 1.66 | 1.57 | 1.63 | 251.54K |
Contact Details
About Company
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Company Information
| Employees | 64 |
| Beta | -0.26 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-22.81-2.77%
argenx SE$799.32REGN-14.62-2.05%
Regeneron Pharmaceuticals, Inc.$698.25UTHR-7.21-1.25%
United Therapeutics Corporation$568.58MDGL-16.2-3.00%
Madrigal Pharmaceuticals, Inc.$523.69VRTX-13.46-2.99%
Vertex Pharmaceuticals Incorporated$436.95PRAX-2.94-0.85%
Praxis Precision Medicines, Inc.$342.58KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS-10.01-3.16%
Krystal Biotech, Inc.$306.29ALNY-6.47-2.20%
Alnylam Pharmaceuticals, Inc.$286.98ASND-4.99-2.03%
Ascendis Pharma A/S$240.50Company Overview
Boundless Bio, Inc. (NASDAQ:BOLD) closed at $1.49 USD, losing -$0.06 (-3.87%) from the previous close of $1.55. The stock is currently mid-range between its 52-week high and low $0.96 and $1.73. With a market capitalization of about $33.47 million, Boundless Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.95). Key stats such as the average daily volume over the past year has been around 216.16 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Boundless Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zachary Hornby, the company employs approximately 64 people and listed since July 20, 2016. Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.
Technical Performance
BOLD has shown mixed momentum, losing -0.81% over the past week and -10.22% over the past quarter, though year-to-date performance is up 2.5%. Short-term trend indicators are bullishly aligned (SMA20 1.78%, SMA50 -2.86%, SMA200 -3.82%). The stock’s 14-day RSI is 48.9 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.41% below its high and over 20.68% above its low. Average 10-day trading volume of 203.85 thousand shares is in line with the 3-month average of 218.82 thousand, indicating normal recent market interest.
Earnings & Analyst Outlook
Wall Street analysts project EPS growth of 35.77% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 168.46% upside. The low target suggests 168.46% downside. The mean target is $4.00. This offers 168.46% upside. Boundless Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 08, 2026, missed forecasts by 4.05%. The prior quarter beat by 31.82%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 27, 2025.
Frequently Asked Questions
What is the current Boundless Bio, Inc. (BOLD) stock price?
Boundless Bio, Inc. (NASDAQ: BOLD) stock price is $1.49 in the last trading session. During the trading session, BOLD stock reached the peak price of $1.56 while $1.49 was the lowest point it dropped to. The percentage change in BOLD stock occurred in the recent session was -3.87% while the dollar amount for the price change in BOLD stock was - $0.06.
BOLD's industry and sector of operation?
The NASDAQ listed BOLD is part of Biotechnology industry that operates in the broader Healthcare sector. Boundless Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of BOLD?
No Data
How BOLD did perform over past 52-week?
BOLD's closing price is 55.05% higher than its 52-week low of $0.96 where as its distance from 52-week high of $1.73 is -13.62%.
How many employees does BOLD have?
Number of BOLD employees currently stands at 64.
Link for BOLD official website?
Official Website of BOLD is: https://boundlessbio.com
How do I contact BOLD?
BOLD could be contacted at phone 858 766 9912 and can also be accessed through its website. BOLD operates from 9880 Campus Point Drive, San Diego, CA 92121, United States.
How many shares of BOLD are traded daily?
BOLD stock volume for the day was 157.85K shares. The average number of BOLD shares traded daily for last 3 months was 216.16K.
What is the market cap of BOLD currently?
The market value of BOLD currently stands at $33.47M with its latest stock price at $1.49 and 22.46M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep